Restructuring drives down Medtronic's income
This article was originally published in Clinica
Medtronic's sales for the year ended April 30 rose 7% to $2.6 billion, while net income was $457 million, compared with $530 million the previous year. Excluding one-off charges of $137 million, largely for restructuring the vascular business, this represents a 12% increase in net income. The effects of foreign currency translation reduced revenues by $103 million in the year.
You may also be interested in...
As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.
Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.